Safety and preliminary efficacy from the phase 1 portion of MasterKey-01: A First-in-human dose-escalation study to determine the recommended phase 2 dose (RP2D), pharmacokinetics (PK) and preliminary antitumor activity of BDTX-189, an inhibitor of allosteric ErbB mutations, in patients (pts) with advanced solid malignancies.

被引：17

作者：

Schram, Alison M.

Ahnert, Jordi Rodon

Patel, Manish R.

Jauhari, Shekeab

Sachdev, Jasgit C.

Zhu, Viola Weijia

LoRusso, Patricia

Nguyen, Danny

Le, Xiuning

O'Connor, Matthew

Waters, Nigel

Cook, Carl

Witt, Karsten

Humphrey, Rachel W.

Janne, Pasi A.

Hamilton, Erika P.

机构：

[1] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[3] Florida Canc Specialists, Sarah Cannon Res Inst, Sarasota, FL USA

[4] Florida Canc Specialists, Sarah Cannon Res Inst, Lake Mary, FL USA

[5] HonorHlth Res Inst, Scottsdale, AZ USA

[6] Univ Calif Irvine, Chao Family Comprehens Canc Ctr, Orange, CA 92668 USA

[7] Yale Univ, Sch Med, New Haven, CT USA

[8] Pacific Shores Med Grp, Long Beach, CA USA

[9] Black Diamond Therapeut Inc, New York, NY USA

[10] Black Diamond Therapeut Inc, Cambridge, MA USA

[11] Dana Farber Canc Inst, Boston, MA 02115 USA

[12] Tennessee Oncol LLC, Sarah Cannon Res Inst, Nashville, TN USA

来源：

关键词：

D O I：

10.1200/JCO.2021.39.15_suppl.3086

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

3086

引用

页数：2

共 32 条